Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/20 11:31:23 am
86.01 CHF   +0.57%
05:59aNOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
02:51aNOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : Genentech Get Expanded FDA OK of Xolair for Nasal Polyps

12/01/2020 | 12:12pm EST

By Colin Kellaher

Novartis AG and Roche Holding AG's Genentech unit on Tuesday said the Food and Drug Administration approved the expanded use of Xolair for the add-on maintenance treatment of nasal polyps in adults with inadequate response to intranasal corticosteroids.

The companies said the approval makes Xolair the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E, a key driver of inflammation.

Nasal polyps, which can lead to nasal congestion and a loss of smell, frequently occur with other respiratory conditions, such as allergies and asthma.

Xolair was already approved in the U.S. to treat moderate to severe persistent allergic asthma and chronic idiopathic urticaria. Novartis and Genentech work together to develop and co-promote Xolair in the U.S.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

12-01-20 1211ET

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 0.57% 86.01 Delayed Quote.2.24%
ROCHE HOLDING AG 0.57% 320 Delayed Quote.2.98%
All news about NOVARTIS AG
05:59aNOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
02:51aNOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
01/19Novartis, GSK Kick Off Exploration of African Genetic Diversity to Improve Tr..
MT
01/19Novartis, GlaxoSmithKline Launch Research on Genetic Diversity in Africa
MT
01/19GSK, Novartis Announce Collaboration To Support Scientific Research Into Gene..
RE
01/19NOVARTIS : GSK and Novartis announce collaboration to support scientific researc..
AQ
01/19NOVARTIS : and GSK announce collaboration to support scientific research into ge..
PU
01/17NOVARTIS : to Continue Global Gene Therapy Access Program in 2021
MT
01/15NOVARTIS : Deutsche Bank Starts Novartis at Buy
MT
More news
Financials (USD)
Sales 2020 49 196 M - -
Net income 2020 8 204 M - -
Net Debt 2020 19 213 M - -
P/E ratio 2020 23,5x
Yield 2020 3,67%
Capitalization 196 B 220 B -
EV / Sales 2020 4,37x
EV / Sales 2021 3,99x
Nbr of Employees 110 000
Free-Float 86,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 108,90 $
Last Close Price 86,01 $
Spread / Highest target 63,7%
Spread / Average Target 26,6%
Spread / Lowest Target -4,48%
EPS Revisions
Managers and Directors
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG2.24%218 823
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160
ABBVIE INC.4.69%198 051